Management of idiopathic pulmonary fibrosis in the elderly patient: Addressing key questions

Keith C. Meyer, Sonye Danoff, Lisa H. Lancaster, Steven D. Nathan

Research output: Contribution to journalArticle

Abstract

Idiopathic pulmonary fibrosis (IPF) is strongly associated with advanced age. Making an accurate diagnosis of IPF is critical, as it remains only one of many potential diagnoses for an elderly patient with newly recognized interstitial lung disease. Optimal management of IPF, especially in older-aged patients, hinges on such factors as balancing the application of standard-of-care measures with the patient's overall health status (robustness vs frailty) and considering the patient's wishes, desires, and expectations. IPF is known to be associated with certain comorbidities that tend to be more prevalent in the elderly population. Until recently, options for the pharmacologic management of IPF were limited and included therapies such as immunosuppressive agents, which may pose substantial risk to the elderly patient. However, the antifibrotic agents pirfenidone and nintedanib have now become commercially available in the United States for the treatment of IPF. The monitoring and treatment of patients with IPF, especially elderly patients with comorbid medical conditions, require consideration of adverse side effects, the avoidance of potential drug-drug interactions, treatment of comorbidities, and the timely implementation of supportive and palliative measures. Individualized counseling to guide decision-making and enhance quality of life is also integral to optimal management of the elderly patient with IPF.

Original languageEnglish (US)
Pages (from-to)242-252
Number of pages11
JournalChest
Volume148
Issue number1
DOIs
StatePublished - Jul 1 2015

Fingerprint

Idiopathic Pulmonary Fibrosis
Comorbidity
Interstitial Lung Diseases
Physiologic Monitoring
Therapeutics
Standard of Care
Immunosuppressive Agents
Drug Interactions
Health Status
Counseling
Decision Making
Quality of Life

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine
  • Medicine(all)

Cite this

Management of idiopathic pulmonary fibrosis in the elderly patient : Addressing key questions. / Meyer, Keith C.; Danoff, Sonye; Lancaster, Lisa H.; Nathan, Steven D.

In: Chest, Vol. 148, No. 1, 01.07.2015, p. 242-252.

Research output: Contribution to journalArticle

Meyer, Keith C. ; Danoff, Sonye ; Lancaster, Lisa H. ; Nathan, Steven D. / Management of idiopathic pulmonary fibrosis in the elderly patient : Addressing key questions. In: Chest. 2015 ; Vol. 148, No. 1. pp. 242-252.
@article{357d0c1697174fd39f2ca87979705286,
title = "Management of idiopathic pulmonary fibrosis in the elderly patient: Addressing key questions",
abstract = "Idiopathic pulmonary fibrosis (IPF) is strongly associated with advanced age. Making an accurate diagnosis of IPF is critical, as it remains only one of many potential diagnoses for an elderly patient with newly recognized interstitial lung disease. Optimal management of IPF, especially in older-aged patients, hinges on such factors as balancing the application of standard-of-care measures with the patient's overall health status (robustness vs frailty) and considering the patient's wishes, desires, and expectations. IPF is known to be associated with certain comorbidities that tend to be more prevalent in the elderly population. Until recently, options for the pharmacologic management of IPF were limited and included therapies such as immunosuppressive agents, which may pose substantial risk to the elderly patient. However, the antifibrotic agents pirfenidone and nintedanib have now become commercially available in the United States for the treatment of IPF. The monitoring and treatment of patients with IPF, especially elderly patients with comorbid medical conditions, require consideration of adverse side effects, the avoidance of potential drug-drug interactions, treatment of comorbidities, and the timely implementation of supportive and palliative measures. Individualized counseling to guide decision-making and enhance quality of life is also integral to optimal management of the elderly patient with IPF.",
author = "Meyer, {Keith C.} and Sonye Danoff and Lancaster, {Lisa H.} and Nathan, {Steven D.}",
year = "2015",
month = "7",
day = "1",
doi = "10.1378/chest.14-2475",
language = "English (US)",
volume = "148",
pages = "242--252",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "1",

}

TY - JOUR

T1 - Management of idiopathic pulmonary fibrosis in the elderly patient

T2 - Addressing key questions

AU - Meyer, Keith C.

AU - Danoff, Sonye

AU - Lancaster, Lisa H.

AU - Nathan, Steven D.

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Idiopathic pulmonary fibrosis (IPF) is strongly associated with advanced age. Making an accurate diagnosis of IPF is critical, as it remains only one of many potential diagnoses for an elderly patient with newly recognized interstitial lung disease. Optimal management of IPF, especially in older-aged patients, hinges on such factors as balancing the application of standard-of-care measures with the patient's overall health status (robustness vs frailty) and considering the patient's wishes, desires, and expectations. IPF is known to be associated with certain comorbidities that tend to be more prevalent in the elderly population. Until recently, options for the pharmacologic management of IPF were limited and included therapies such as immunosuppressive agents, which may pose substantial risk to the elderly patient. However, the antifibrotic agents pirfenidone and nintedanib have now become commercially available in the United States for the treatment of IPF. The monitoring and treatment of patients with IPF, especially elderly patients with comorbid medical conditions, require consideration of adverse side effects, the avoidance of potential drug-drug interactions, treatment of comorbidities, and the timely implementation of supportive and palliative measures. Individualized counseling to guide decision-making and enhance quality of life is also integral to optimal management of the elderly patient with IPF.

AB - Idiopathic pulmonary fibrosis (IPF) is strongly associated with advanced age. Making an accurate diagnosis of IPF is critical, as it remains only one of many potential diagnoses for an elderly patient with newly recognized interstitial lung disease. Optimal management of IPF, especially in older-aged patients, hinges on such factors as balancing the application of standard-of-care measures with the patient's overall health status (robustness vs frailty) and considering the patient's wishes, desires, and expectations. IPF is known to be associated with certain comorbidities that tend to be more prevalent in the elderly population. Until recently, options for the pharmacologic management of IPF were limited and included therapies such as immunosuppressive agents, which may pose substantial risk to the elderly patient. However, the antifibrotic agents pirfenidone and nintedanib have now become commercially available in the United States for the treatment of IPF. The monitoring and treatment of patients with IPF, especially elderly patients with comorbid medical conditions, require consideration of adverse side effects, the avoidance of potential drug-drug interactions, treatment of comorbidities, and the timely implementation of supportive and palliative measures. Individualized counseling to guide decision-making and enhance quality of life is also integral to optimal management of the elderly patient with IPF.

UR - http://www.scopus.com/inward/record.url?scp=84937547555&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937547555&partnerID=8YFLogxK

U2 - 10.1378/chest.14-2475

DO - 10.1378/chest.14-2475

M3 - Article

C2 - 26149553

AN - SCOPUS:84937547555

VL - 148

SP - 242

EP - 252

JO - Chest

JF - Chest

SN - 0012-3692

IS - 1

ER -